2023 年第一季度报告 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2023 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息 的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 | | 单位：元 | | 币种：人民币 | | --- | --- | --- | --- | | 项目 | 本报告期 | 本报告期比上年同 | | | | | 期增减变动幅度 | | | | | (%) | | | 营业收入 | 237,720,069.60 | | -49.04 | | 归属于上市公司股东的净利润 | 38,395,308.10 | | -67.79 | | 归属于上市公司股东的扣除非经常 | 17,819,514.67 | | ...

2022 年年度报告 公司代码：688553 公司简称：汇宇制药 四川汇宇制药股份有限公司 2022 年年度报告 三、 重大风险提示 在 2023 至 2025 年以至未来几年国家集采常态化的情况下，公司产品，包括已上市和未来取 得上市资格的产品，面临在国家不同批次集采中首批次中标和多轮次续标中销售价格下降、中选 区域减少导致的单产品销售收入降低的风险，进而导致公司主营业务收入大幅下降或大幅波动的 风险。 1 / 255 公司其他重大风险，请参见在本报告中详细描述在经营过程中可能存在的相关风险及应对措 施，具体内容详见本报告第三节"管理层讨论与分析"之四、风险因素"。 2022 年年度报告 重要提示 □是 √否 四、 公司全体董事出席董事会会议。 五、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 √适用 □不适用 2 / 255 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 经天健会计师事务所（特殊普通合伙）审计，截至2022 ...

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 248,990,617.28 for the year 2022, with a cumulative distributable profit of RMB 816,516,589.68 as of December 31, 2022[6]. - The proposed cash dividend is RMB 2.35 per 10 shares (including tax), totaling RMB 99,546,000.00, which represents 40.00% of the net profit attributable to shareholders for 2022[6]. - The company's operating revenue for 2022 was approximately ¥1.49 billion, a decrease of 18.12% compared to ¥1.82 billion in 2021[37]. - The net profit attributable to shareholders decreased by 44.15% to ¥248.99 million in 2022 from ¥445.86 million in 2021[37]. - The basic earnings per share dropped by 50.83% to ¥0.59 in 2022 compared to ¥1.20 in 2021[38]. - The weighted average return on net assets fell to 6.85% in 2022 from 32.59% in 2021, a decrease of 25.74%[39]. - The net cash flow from operating activities decreased by 56.52% to ¥194.06 million in 2022 from ¥446.36 million in 2021[37]. - The company reported a total revenue of approximately ¥5.08 billion for the year 2022, with a net profit of around ¥331.34 million[100]. - The company achieved total operating revenue of 149,326.79 million RMB, a year-on-year decrease of 18.12% due to a significant decline in sales of its main product, pemetrexed disodium injection[130]. - The net profit attributable to shareholders was 24,899.06 million RMB, down 44.15% year-on-year, primarily due to the decline in sales revenue of key products[130]. Shareholder Rights and Governance - The company has established a special voting rights mechanism, where the actual controller holds special shares with five times the voting power of ordinary shares[9]. - As of the report date, the actual controller holds 31.28% of the total shares and 60.95% of the voting rights[12]. - The company has implemented measures to protect minority shareholders' interests, including the right to convene extraordinary general meetings and propose agenda items[15]. - The supervisory board will monitor the operation of the special voting rights mechanism to prevent abuse and ensure compliance with regulations[16]. - The independent directors are tasked with overseeing the company's governance and ensuring compliance with relevant laws and regulations[17]. - The company will strictly adhere to the disclosure requirements of the Shanghai Stock Exchange regarding special voting rights arrangements in its periodic reports[20]. - The company emphasizes that forward-looking statements regarding future plans and strategies do not constitute a substantive commitment to investors, highlighting the importance of investment risk awareness[21]. - The company is committed to enhancing information disclosure management to protect investors' legal rights[20]. Research and Development - Research and development expenses increased by 43.50% to ¥356.19 million in 2022 from ¥248.21 million in 2021[37]. - The proportion of R&D investment to operating revenue increased to 23.85% in 2022 from 13.61% in 2021, an increase of 10.24%[39]. - The company has established four research institutes to enhance its capabilities in developing high-quality generic and innovative drugs, ensuring a robust pipeline[59]. - The company is focusing on enhancing its product portfolio with high-quality generic drugs to ensure sustainable growth in the future[50]. - The company is actively developing innovative drugs in oncology, with 12 projects in progress, including 7 small molecule drugs and 5 large molecule drugs, and has initiated 2 new projects during the reporting period[57]. - The company has completed FDA certification for its production quality management system, meeting international standards for entry into the U.S. market[53]. - The company has made significant progress in complex formulation production and quality control technologies, including advanced techniques for polymer excipient preparation and purification[82]. - The company has established advanced drug technology platforms, including consistency evaluation for generic drugs and quality control for raw materials[180]. - The company is focusing on innovative drug development, particularly in the oncology field, with a commitment to addressing clinical needs and reducing adverse reactions[104]. Market and Sales - The company has expanded its international market presence, with 18 products approved for sale abroad and nearly 270 registrations held, covering over 56 countries, including new sales in 9 countries in 2022[55]. - The domestic sales model primarily targets grade hospitals, utilizing bulk purchasing and academic promotion, while international sales are mainly conducted through a consignment model via subsidiaries[58]. - The company has a strong international registration system, enabling rapid global submissions and approvals, enhancing its competitive edge in international markets[87]. - The company has established partnerships for drug approvals in regions like Canada and the UAE[192]. - The company is strategically positioning itself in the oncology market with multiple anti-tumor products currently under review[188]. Risk Factors - The company has detailed risk factors and corresponding countermeasures in its management discussion and analysis section[4]. - The company faces risks related to intensified competition in the market, particularly concerning its main products entering volume-based procurement[110]. - The company is subject to environmental regulations that may increase operational costs if stricter standards are implemented in the future[112]. - The company is at risk of losing core technical personnel, which is critical for maintaining its competitive edge in R&D and production[109]. - The company faces risks from industry policy changes, price declines of drugs, and increased market competition, which could adversely affect business and profitability[125][126][128]. Product Development and Pipeline - The company is focusing on expanding its pipeline with innovative drugs, aiming for first-in-class and best-in-class status in the market[92]. - The company has several ongoing projects, including a biological innovative drug (HY-0001) with a total investment of CNY 430,000,000, currently in laboratory research, expected to enter preclinical studies in 2023[91]. - The company plans to launch multiple new drugs domestically and seek overseas authorization, targeting various cancers including non-small cell lung cancer and pancreatic cancer[91]. - The company is developing new technologies and formulations, including a combination product with G-CSF for mobilizing stem cells in patients[190]. - The company is actively pursuing regulatory approvals for its innovative therapies targeting serious health conditions, including various cancers and toxicities[96]. Financial Management - The company received government subsidies amounting to 12.90 million yuan during the reporting period, which are crucial for its operational performance[121]. - The company's financial expenses were -46,898,621.39 RMB, a significant reduction compared to the previous year, due to increased interest income from cash management[134]. - The company reported a net cash outflow from financing activities of 99.99 million yuan, a decrease of 244.72 million yuan year-on-year, mainly due to dividend payments[135]. - The company’s other income decreased by 48.97% to 12.90 million yuan, primarily due to a reduction in government subsidies[135]. - The company’s credit impairment losses increased by 48.5% to 7.70 million yuan, mainly due to an increase in bad debt provisions for other receivables[135].

证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------|----------------------------------|----------------------------|--------------------------------------------------------------| | | | | 编号： 2022-005 | | | 特定对象调研 | 分析师会议 | | | | 媒体采访 | 业绩说明会 | | | | 新闻发布会 | 路演活动 | | | | 现场参观 | | | | | 其他 | （请文字说明其他活动内容） | | | | 华安证券、融通基金、博鸿资产 | | | | | 2022 年 5月31 日 | 10:30-12:00 | | | | 四川汇宇制药股份有限公司现场交流 | | | | | | | | | | | | 董事长、总经理：丁兆先生；研究院副院长：陈寿军先生、胡和平先 | | | | | 生；董事会秘书：刘静默女士；投资者关系管理专员：王游春 ...

2022 年第三季度报告 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 | 年初至报告期末 | 年初至报告期 | | --- | --- | --- | --- | --- | | | | 上年同期增 | | 末比上年同期 | | | | 减变动幅度 | | 增减变动幅度 | | | | (%) | | (%) | | 营业收入 | 386,863,922.44 | -23.65 | 1,220,116,9 ...

2022 年半年度报告 公司代码：688553 公司简称：汇宇制药 四川汇宇制药股份有限公司 2022 年半年度报告 1 / 184 2022 年半年度报告 重要提示 一、本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、重大风险提示 公司已在本报告中详细描述在经营过程中可能存在的相关风险及应对措施，具体内容详见本 报告第三节"管理层讨论与分析"之五、风险因素"。 三、公司全体董事出席董事会会议。 六、董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、是否存在公司治理特殊安排等重要事项 √适用 □不适用 （一）特别表决权设置情况 1、特别表决权设置基本情况 2020年5月27日，公司召开2020年第一次临时股东大会，审议通过了《关于<四川汇宇制药股 份有限公司关于设置特别表决权股份的方案>的议案》《关于修改后的<四川汇宇制药股份有限公 司章程>的议案》，对《公司章程》进行了修改，完成特别表决权股份的设置。 2020年5月28日，公司在内江市市场监督管理局完成设置特别表决权的《公司章 ...

2022 年第一季度报告 证券代码：688553 证券简称：汇宇制药 四川汇宇制药股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人丁兆、主管会计工作负责人高岚及会计机构负责人梁多辉（会计主管人员）保证季度 报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | 项目 | 本报告期 | | 本报告期比上年 同期增减变动幅 | | | --- | --- | --- | --- | --- | | | | | 度(%) | | | 营业收入 | | 466,465,985.28 | | 9.18 | | 归属于上市公司股东的净利润 | | 119,193,479.87 | | -11.49 | | 归属于上市公司股东的扣除非经 常性损益的 ...

1 / 247 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 2021 年年度报告 公司代码：688553 公司简称： 汇宇制药 四川汇宇制药股份有限公司 2021 年年度报告 五、 天健会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 六、 公司负责人丁兆、主管会计工作负责人高岚及会计机构负责人（会计主管人员）梁多辉声明： 保证年度报告中财务报告的真实、准确、完整。 七、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 经公司董事会审议通过的2021年度利润分配预案为：公司拟以实施权益分派股权登记日登记 的总股本为基数分配利润，拟向全体股东每10股派发现金红利2.11元（含税）。截至2021年12月 31日，公司总股本为423,600,000股，以此计算拟派发现金红利合计89,379,600.00元（含税）。 本年度公司现金分红占归属于母公司股东的净利润比例为20.05%，本次利润分配后，剩余 ...